Business
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08,
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31, 2024. The company also repurchased 2.0 million shares of its common stock during the fourth quarter. “We closed 2025 having achieved another year of solid execution and meaningful progress advancing our 5x30 strategic priorities, leaving us well-positioned for sustainable, long-term success,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “Strong EXPAREL volume growth in the second half of the year underscores the value of our commercial investments and positions us for significant and sustainable revenues moving forward. We enter 2026 with momentum that provides us with a strong foundation and clear line of sight to further operational progress and an exciting chapter of growth ahead.” Preliminary Unaudited Fourth Quarter Revenue Highlights Fourth quarter EXPAREL net product sales of $155.8 million in 2025, compared with $147.7 million in 2024. Fourth quarter volume growth of 7 percent was partially offset by a shift in vial mix and discounting associated with the launch of a new group purchasing organization (GPO) partnership.Fourth quarter ZILRETTA net product sales of $33.0 million in 2025, compared with $33.1 million in 2024.Fourth quarter iovera° net product sales of $7.0 million in 2025, compared with $6.5 million in 2024.Other revenue, comprised of sales of bupivacaine liposome injectable suspension, was $1.1 million in the fourth quarter of 2025, compared with zero in the fourth quarter of 2024. Preliminary Unaudited Full-Year Revenue Highlights Full-year EXPAREL net product sales of $575.1 million in 2025, compared with $549.0 million in 2024. Full-year volume growth of 6 percent was partially offset by a shift in vial mix and discounting associated with the company’s new GPO partnerships.Full-year ZILRETTA net product sales of $116.6 million in 2025, compared with $118.1 million in 2024.Full-yea...